Multicenter evaluation of a fully automated screening test, VIDAS HIV 1 + 2, for antibodies to human immunodeficiency virus types 1 and 2.
A multicenter study was done to evaluate the sensitivity, specificity, and efficiency of a new screening test for the simultaneous detection of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) antibodies. The VIDAS HIV 1 + 2 (bioMérieux, Marcy l'Etoile, France) is a fully automated enzyme-linked fluorescent immunoassay that uses synthetic peptides from immunodominant regions of gp41 of HIV-1 and gp36 of HIV-2 as antigens. A total of 2,984 samples were evaluated with this system in six different laboratories, and the results were compared to those obtained with other enzyme-linked immunosorbent assays. The VIDAS HIV 1 + 2 assay showed a very good performance in terms of sensitivity (100%) and specificity (99.6%), requiring minimal manipulation and short incubation time (32 min) to give results similar to or better than those of the other enzyme-linked immunosorbent assays used for screening.
Azevedo-Pereira
J M
JM
Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Portugal.
Lourenço
M H
MH
Barin
F
F
Cisterna
R
R
Denis
F
F
Moncharmont
P
P
Grillo
R
R
Santos-Ferreira
M O
MO
D004797:Enzyme-Linked Immunosorbent Assay; D015483:HIV Antibodies / Q000032:analysis*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D012680:Sensitivity and Specificity
D015483:HIV Antibodies